Compare Campbell Soup Co. (CPB) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs DexCom, Inc. — how do they compare? Campbell Soup Co. trades at $21.97 (market cap $6.59B), while DexCom, Inc. trades at $76.3 (market cap $28.60B). The key difference: DexCom, Inc. is far larger — about 4.3× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays a 7.06% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| CPB | DXCM | |
|---|---|---|
Market Cap | $6.59B | $28.60B |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $89.53 |
52-Week Low | $20.00 | $54.84 |
Enterprise Value | $13.20B | $27.57B |
Dividend Yield | 7.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $22.15, up 0.36% with neutral technical signals. The stock shows modest valuation metrics with P/E of 10.85 and P/S of 0.67, while recent earnings show mixed results with Q1 2026 beating expectations. Revenue growth remains stable at $10.25B for 2025, though profit margins have compressed from historical levels. The company maintains strong cash flow generation and recently launched new product innovations including protein soups and gluten-free options.
CPB offers value investors an attractive 7% dividend yield and reasonable valuation, but faces margin pressure and competitive headwinds. Analyst consensus leans cautious with 58.6% hold ratings, though recent product launches and cost initiatives provide potential catalysts. Key risks include ongoing margin compression and consumer spending sensitivity in the current economic environment.
DXCM trades at $76.35, up 1.85% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 17.93% net income margin and consistent earnings beats. Recent regulatory approvals for G7 15-day CGM in Canada and pediatric clearance for Stelo OTC system highlight growth catalysts. Revenue growth accelerated to $4.66 billion in 2025, up from $4.0 billion in 2024.
DXCM presents a compelling growth story with expanding CGM market access and strong analyst support (80% buy ratings). Key risks include GLP-1 adoption impact on core market and execution of Type 2 non-insulin patient expansion. The stock trades at a premium valuation (P/E 32.76) but offers upside to consensus target of $83.78. Near-term focus on Q2 2026 earnings release July 30.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
